Materialise says that its Mimics Innovation Suite, a set of tools that allows biomedical professionals to perform an array of operations based on medical imaging data, is increasingly used in U.S. hospitals and other clinical settings, which is driving the need for additional resources. The expansion further enables a complete range of 3D surgical planning options to support patient-specific treatment, and the capacity to expedite supply of anatomical models in the United States, the company adds.
By providing virtual planning software linked with fully integrated 3D-printing services, Materialise enables clinicians and surgeons to simulate procedures and evaluate the best options for patient-specific treatments. The system also facilitates communication with patients, co-workers and surgical teams.
Materialise HeartPrint, for instance, which is registered as a Class I medical device in the United States, aids cardiovascular specialists in helping plan patient care and select the necessary tools to treat complex cases such as congenital heart surgery or aortic aneurysm interventions.
Materialise, which is celebrating a quarter century in the additive manufacturing arena, has been a key player in applying 3D printing to biomedical research. It also recently revealed that it was 3D printing plastic parts for the Airbus A350 XWB in its Factory for 3D printing.
